These results suggested that the SULT1E1+ subpopulation in high‐grade meningiomas may directly contribute to the formation of an immunosuppressive environment, which is a common characteristic of aggressive tumors.[30] Targeting the CSF1‐CSF1R axis has been suggested as a potential treatment strategy for malignant meningiomas,[24b] and combination therapies targeting both CSF1‐CSF1R axis and SULT1E1+ subpopulation may be a more effective immunotherapy for high‐grade meningiomas. The gene discussed is CSF1R; the disease is Anaplastic (Malignant) Meningioma.